Pde4

Top News

• Prifemilast Demonstrates Superior Efficacy vs. Apremilast in Newsoara's Head-to-Head Phase 3 Psoriasis Trial; cAMPfield Advancing the Potential Best-in-Class Oral PDE4 Inhibitor in IBD

  PR Newswire 2026-10-09, 10:47

  In a head-to-head Phase 3 trial, prifemilast nearly doubled the rate of PASI 75 response compared with...

• Prifemilast Demonstrates Superior Efficacy vs. Apremilast in Newsoara’s Head-to-Head Phase 3 Psoriasis Trial; cAMPfield Advancing the Potential Best-in-Class Oral PDE4 Inhibitor in IBD (cAMPfield Therapeutics Inc)

  Public Technologies 2026-10-09, 10:01

  ) San Diego, October 9, 2026 - cAMPfield Therapeutics, Inc. (cAMPfield), a clinical-stage biopharmaceutical...